The ENVIROMED project has published a new policy brief titled “Reducing the Environmental Footprint of Pharmaceuticals Across the Lifecycle: Evidence and Policy-Relevant Recommendations from the ENVIROMED Project.”
The publication presents a set of evidence-based recommendations developed through the collaborative work of the ENVIROMED consortium, highlighting how research and innovation can support more sustainable pharmaceutical systems across Europe.
Drawing on the project’s integrated findings, the policy brief explores key areas including pharmaceutical design, manufacturing processes, environmental monitoring, and ecotoxicity assessment. It identifies opportunities to strengthen upstream prevention measures, improve production efficiency, and enhance environmental risk assessment practices throughout the pharmaceutical lifecycle.
The recommendations are closely connected to existing European Union policy frameworks related to environmental risk assessment, chemicals management, water protection, and sustainable production. By linking scientific evidence with policy priorities, the brief demonstrates how innovation, monitoring, and data-driven approaches can contribute to achieving EU sustainability goals.
ENVIROMED adopts a lifecycle perspective, recognising the importance of addressing the environmental impact of pharmaceuticals from development and production to use and disposal. The policy brief therefore provides valuable insights for policymakers, researchers, industry stakeholders, and environmental experts working towards greener and more resilient healthcare systems.
